April 6, 1998
Ono Pharmaceutical Establishes Local Subsidiaries in the U.S. and U.K.
Ono Pharmaceutical Co., Ltd. has established wholly-owned subsidiaries in
the United States and United Kingdom for the primary purpose of
strengthening its development platforms in the U.S. and Europe. The new
subsidiaries are Ono Pharma UK Ltd and Ono Pharma USA, Inc. The new
companies will begin operations April 2.
OPUK's business office is located in London, and Mr. Katsura Kasahara
has been appointed managing director. The company is capitalized at 50,000
pounds and employs eight people. OPUK's main activities include (1) clinical
development of new drugs it has developed, (2) out-licensing and
in-licensing activities, and (3) research on medical practices and health
care outside Japan. Local clinical development is currently in progress
through CRO and focuses on PI testing of the antitumor agent ONO-4007, the
cerebral infarction therapeutic agent ONO-2506, and the peripheral
circulatory disorder therapeutic agent ONO-1608.
The OPUSA business office is located in Hackensack, New Jersey. Mr.
Yoshitaka Konishi has been appointed president. The company is capitalized
at 300,000 dollars and employs six people. OPUSA's activities are similar to
those of OPUK while also encompassing the search for discovery and
exploratory seeds. Although Ono Pharmaceutical has not conducted clinical
development in the U.S. prior to this, application for clinical testing of
ONO-2506 is scheduled for the second half of 1998.
The setting up of local subsidiaries in the U.K. and U.S. enables Ono
Pharmaceutical to finalize the establishment of a three-way simultaneous
development platform in Japan, Europe, and the U.S. Steps will be taken to
strengthen the capabilities of personnel, including the employment of local
employees, to promote the development of international pharmaceuticals that
satisfy global standards. In the medium and long terms, Ono Pharmaceutical
will develop expertise in independent overseas development and the
acquisition of approvals so as to strengthen its foundation of overseas
business deployment while taking into consideration marketing of its own
products in the future.